Crinetics' Once-Daily Oral Paltusotine Achieved the Primary

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an...

Related Keywords

United States ,Corey Davis ,Chas Schultz ,Ir Corporate Communications ,Nasdaq ,Crinetics Pharmaceuticals ,Securities Exchange ,Crinetics Pharmaceuticals Inc ,Paltusotine Maintained ,Were Maintained ,After Switching ,Injected Depot Standard ,Acromegaly Symptom Diary Scores Were Maintained ,Was Well Tolerated ,Serious Adverse ,Will Host ,Conference Call Monday ,Data Review Conference Call ,Securities Act ,Securities Exchange Act ,Nasdaq Crnx ,Nc ,